logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
17/06/2025
LiLai: The monthly cost for all approved doses of Zepbound (teriparatide) is $499 or lower.
Latest
3 m ago
Bank of America: Cracks appearing in foreign demand for US Treasuries.
5 m ago
European natural gas futures surged and then fell back, as investors' concerns about the impact of the latest round of conflict between Israel and Iran on the supply side eased.
11 m ago
JBS (JBS.US) receives initial coverage from Goldman Sachs, given a buy rating with a target price of $19.50.
13 m ago
B of A Securities: Downgrade Sarepta Therapeutics (SRPT.US) rating from Buy to Neutral, target price adjusted from $76.00 to $28.00.
22 m ago
The Bank of Montreal in Canada: lowered the rating of Sarepta Therapeutics (SRPT.US) from outperform to market perform, and adjusted the target price from $120.00 to $70.00.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.